New York, Feb 24, 2026, 05:51 ET — Premarket
- IBRX up about 1% premarket after sharp gains in the prior session
- Company reported 2025 ANKTIVA net product revenue of about $113 million
- Investors eye follow-through at the open and next regulatory steps in 2026
ImmunityBio shares were up about 1% in premarket trading on Tuesday, after the company’s latest update on ANKTIVA sales and new market authorizations sparked heavy buying in the prior session. The stock closed at $9.83 on Monday, up about 13%, on volume well above recent averages. (Marketchameleon)
The move matters because ImmunityBio is one of the smaller biotech names that now has a marketed product and a revenue line that is starting to look like something investors can model, not just argue about.
Traders have been quick to reward anything that hints at repeatable demand, especially when it comes with new geographies and potential new cancer settings. They have also been quick to punish the opposite.
ImmunityBio said ANKTIVA net product revenue rose about 700% year on year in 2025 to roughly $113 million, and fourth-quarter net product revenue was $38.3 million. Net loss attributable to common stockholders was $351.4 million for 2025, while cash, cash equivalents and marketable securities totaled $242.8 million at year-end, according to the company. Founder and executive chairman Patrick Soon-Shiong called the Saudi lung-cancer authorization “a defining moment,” while CEO Richard Adcock said the company is aiming for “disciplined execution,” including a biologics license application, or BLA, filing targeted for the fourth quarter of 2026 in a bladder-cancer trial. (Business Wire)
A regulatory filing showed the company issued the business update and financial results release on Monday and furnished it under an 8-K. (SEC)
ANKTIVA (nogapendekin alfa inbakicept) is an immune-stimulating therapy that ImmunityBio is selling for a form of early-stage bladder cancer. It is used with BCG, a long-used bladder treatment that uses a weakened bacterium to trigger an immune response.
The company said the bladder-cancer use is now authorized across the United States, the United Kingdom, the European Union and Saudi Arabia, covering 33 countries in total. It also flagged a response submitted to the U.S. FDA for additional data in a papillary-only bladder cancer setting and said it is awaiting the agency’s review.
ImmunityBio also said Saudi regulators granted conditional accelerated approval in January for ANKTIVA in combination with checkpoint inhibitors in metastatic non-small cell lung cancer, and it expects a commercial launch there within 60 days of approval. Checkpoint inhibitors are a class of drugs that take the brakes off immune cells; they are a backbone of lung-cancer care.
Even with Monday’s jump, the setup is not clean. Conditional or accelerated approvals typically come with follow-up requirements, and expansion plans can slip on timelines, supply and reimbursement.
For Tuesday, the immediate tell will be whether Monday’s burst of volume turns into sustained buying after the opening bell, or fades into profit-taking. Biotech momentum trades can flip fast.
